These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 9325559)

  • 1. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine.
    Malhotra AK; Adler CM; Kennison SD; Elman I; Pickar D; Breier A
    Biol Psychiatry; 1997 Oct; 42(8):664-8. PubMed ID: 9325559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation.
    Duncan GE; Leipzig JN; Mailman RB; Lieberman JA
    Brain Res; 1998 Nov; 812(1-2):65-75. PubMed ID: 9813244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.
    Anand A; Charney DS; Oren DA; Berman RM; Hu XS; Cappiello A; Krystal JH
    Arch Gen Psychiatry; 2000 Mar; 57(3):270-6. PubMed ID: 10711913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
    Krystal JH; Karper LP; Seibyl JP; Freeman GK; Delaney R; Bremner JD; Heninger GR; Bowers MB; Charney DS
    Arch Gen Psychiatry; 1994 Mar; 51(3):199-214. PubMed ID: 8122957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism.
    Duncan GE; Miyamoto S; Leipzig JN; Lieberman JA
    J Pharmacol Exp Ther; 2000 Apr; 293(1):8-14. PubMed ID: 10734147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
    Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G
    Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia.
    Goff DC; Henderson DC; Evins AE; Amico E
    Biol Psychiatry; 1999 Feb; 45(4):512-4. PubMed ID: 10071726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.
    Malhotra AK; Pinals DA; Adler CM; Elman I; Clifton A; Pickar D; Breier A
    Neuropsychopharmacology; 1997 Sep; 17(3):141-50. PubMed ID: 9272481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation.
    Gray L; van den Buuse M; Scarr E; Dean B; Hannan AJ
    Int J Neuropsychopharmacol; 2009 Feb; 12(1):45-60. PubMed ID: 18593507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-serine added to clozapine for the treatment of schizophrenia.
    Tsai GE; Yang P; Chung LC; Tsai IC; Tsai CW; Coyle JT
    Am J Psychiatry; 1999 Nov; 156(11):1822-5. PubMed ID: 10553752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.
    Malhotra AK; Pinals DA; Weingartner H; Sirocco K; Missar CD; Pickar D; Breier A
    Neuropsychopharmacology; 1996 May; 14(5):301-7. PubMed ID: 8703299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
    Large CH
    J Psychopharmacol; 2007 May; 21(3):283-301. PubMed ID: 17591656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological modulation of the effects induced by ketamine at subanesthetic doses].
    Mechri A; Micallef J; Blin O; Saoud M; Daléry J; Gaha L
    Therapie; 2001; 56(5):617-22. PubMed ID: 11806303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo.
    Bressan RA; Erlandsson K; Stone JM; Mulligan RS; Krystal JH; Ell PJ; Pilowsky LS
    Biol Psychiatry; 2005 Jul; 58(1):41-6. PubMed ID: 15992521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ketamine on brain function during response inhibition.
    Steffens M; Neumann C; Kasparbauer AM; Becker B; Weber B; Mehta MA; Hurlemann R; Ettinger U
    Psychopharmacology (Berl); 2018 Dec; 235(12):3559-3571. PubMed ID: 30357437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia.
    Duncan GE; Zorn S; Lieberman JA
    Mol Psychiatry; 1999 Sep; 4(5):418-28. PubMed ID: 10523814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine.
    Duncan GE; Miyamoto S; Leipzig JN; Lieberman JA
    Brain Res; 1999 Oct; 843(1-2):171-83. PubMed ID: 10528123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome.
    Buchanan RW; Breier A; Kirkpatrick B; Ball P; Carpenter WT
    Am J Psychiatry; 1998 Jun; 155(6):751-60. PubMed ID: 9619146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.